Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 30, 2026 20:13 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 15,940 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0000914190-26-000142 · form4.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,940 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2026 Filed Sep 30, 2026 20:13 UTC |
HIGGINS JOHN LDirector
|
Tax withholdingCommon Stock | 5,562 | $72.51 | $403,300.62 |
DisclosureSEC source: 0000914190-26-000142 · form4.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,254 Read SEC document |
| September 28, 2026 Filed Sep 30, 2026 20:13 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 15,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000142 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 15,940 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,940 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC |
BAUMGARTNER ROBERT VDirector
|
Tax withholdingCommon Stock | 5,559 | $72.55 | $403,305.45 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,884 Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:52 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 15,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000139 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:49 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 18,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000134 · form4.xml · derivative · entry 15 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,432 Underlying: Common Stock · 18,432 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 18,432 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 18,432 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:49 UTC |
Bohnen ShaneSVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 11,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000134 · form4.xml · derivative · entry 14 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,344 Underlying: Common Stock · 11,344 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 93,582 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000133 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,582 Underlying: Common Stock · 93,582 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13 · derivative.exercise_date: 93,582 restricted stock units vest on 8/17/2029. F13 · derivative.expiration_date: 93,582 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 57,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000133 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,590 Underlying: Common Stock · 57,590 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 36,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000132 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,459 Underlying: Common Stock · 36,459 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 36,459 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 36,459 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 22,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000132 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,438 Underlying: Common Stock · 22,438 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC |
Herr Amy E.Director
|
GrantRestricted Stock Units · Derivative | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000131 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,381 Underlying: Common Stock · 1,381 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 23,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000130 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,985 Underlying: Common Stock · 23,985 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 23,985 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 23,985 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 14,762 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000130 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,762 Underlying: Common Stock · 14,762 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029. F10 · derivative.expiration_date: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:46 UTC |
Crouse Steven C.President - Diag & Spatial Bi
|
GrantRestricted Stock Units · Derivative | 14,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000129 · form4.xml · derivative · entry 18 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,140 Underlying: Common Stock · 14,140 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F16 · derivative.exercise_date: 14,140 restricted stock units vest on 8/17/2029. F16 · derivative.expiration_date: 14,140 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:46 UTC |
Crouse Steven C.President - Diag & Spatial Bi
|
GrantRestricted Stock Units · Derivative | 8,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000129 · form4.xml · derivative · entry 17 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,702 Underlying: Common Stock · 8,702 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15 · derivative.exercise_date: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029. F15 · derivative.expiration_date: 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 11,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,569 Underlying: Common Stock · 11,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F14 · derivative.exercise_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. F14 · derivative.expiration_date: 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,543 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,544 Underlying: Common Stock · 8,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F11 · derivative.expiration_date: 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 24,324 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 13 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,621 Underlying: Common Stock · 24,324 shares Expires 2031-02-01 F8 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,621 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 12 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,835 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 11 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,835 Underlying: Common Stock · 588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 22,389 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 8 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,492 Underlying: Common Stock · 22,389 shares Expires 2030-08-15 F4 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,492 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,319 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 7 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,319 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · derivative · entry 6 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,319 Underlying: Common Stock · 554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 10,821 | $72.40 | $783,440.40 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,762 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:14 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000122 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,903 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,807 Underlying: Common Stock · 4,903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. F11 · derivative.expiration_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 11 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,011 Underlying: Common Stock · 4,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F7 · derivative.exercise_date: 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. F7 · derivative.expiration_date: 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 34,982 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 8 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,332 Underlying: Common Stock · 34,982 shares Expires 2030-08-15 F4 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,332 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Disposition to issuerPerformance Restricted Stock Units · Derivative | 12,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 7 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,999 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 6 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,999 Underlying: Common Stock · 866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 4,310 | $72.40 | $312,044.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,183 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 9,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,452 Underlying: Common Stock · 3,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F10 · derivative.expiration_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,623 Underlying: Common Stock · 2,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F7 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 22,898 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 7 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,526 Underlying: Common Stock · 22,898 shares Expires not disclosed F5 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited. F5 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,507 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 6 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 567 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 5 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,507 Underlying: Common Stock · 567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 1,976 | $72.40 | $143,062.40 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,943 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionCommon Stock | 6,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 2,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 16 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,664 Underlying: Common Stock · 2,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F12 · derivative.expiration_date: 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 13 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F9 · derivative.expiration_date: 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Disposition to issuerPerformance Restricted Stock Units · Derivative | 4,502 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 11 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,502 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 10 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,502 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. F7 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 300 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Disposition to issuerPerformance Stock Option (Right to Buy) · Derivative | 12,117 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 9 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 12,117 shares Expires not disclosed F6 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 807 performance options. The remainder of the performance options were forfeited. F6 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 807 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · derivative · entry 8 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: 49 restricted stock units vest on 8/15/2026. F5 · derivative.expiration_date: 49 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Tax withholdingCommon Stock | 1,343 | $72.40 | $97,233.20 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · nonDerivative · entry 2 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:42 UTC |
Bohnen ShaneSVP - General Counsel
|
Exercise / conversionCommon Stock | 4,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000116 · form4.xml · nonDerivative · entry 1 Bohnen Shane · CIK 0001969581 · SVP - General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:13 UTC |
Crouse Steven C.President - Diag & Spatial Bi
|
Exercise / conversionRestricted Stock Units · Derivative | 2,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000114 · form4.xml · derivative · entry 7 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,353 Underlying: Common Stock · 2,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.